Selv om det ikke er observeret i kliniske forsøg med lave doser doxycyclin (40 mg/ dag), kan risikoen for at udvikle modstandsdygtighed i den normale mikroflora ikke udelukkes hos patienter, der behandles med ORACEA.
Although not observed during clinical studies with low dose doxycycline (40 mg/ day), the risk for development of resistance in the normal microflora cannot be excluded in patients treated with ORACEA.